Pubblicazioni

Approfondimenti generali

: Melanoma, Linee Guida AIOM, 2017 [Apri]
: Dummer R, et al. Cutaneous Melanoma: ESMO Clinical Practice Guidelines. Ann Oncol 2015; 26 (suppl 5): v126-v132 [Apri]
: ClinicalTrial.gov. A service of the U.S. National Institutes of Health [Apri]

Referenze bibliografiche specifiche

: Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006. ASCO 2016; abs. #9504 [Apri]
: Robert C, et al. Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment. ASCO 2017; abs. #9504 [Apri]
: Long GV, et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. ASCO 2018; abs. #9503 [Apri]